EP0794778A1 - Particule de resine, substance medicale et preparation pharmaceutique contenant cette particule de resine - Google Patents

Particule de resine, substance medicale et preparation pharmaceutique contenant cette particule de resine

Info

Publication number
EP0794778A1
EP0794778A1 EP96900177A EP96900177A EP0794778A1 EP 0794778 A1 EP0794778 A1 EP 0794778A1 EP 96900177 A EP96900177 A EP 96900177A EP 96900177 A EP96900177 A EP 96900177A EP 0794778 A1 EP0794778 A1 EP 0794778A1
Authority
EP
European Patent Office
Prior art keywords
cilostazol
resin particle
vinyl alcohol
alcohol copolymer
ethylene vinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96900177A
Other languages
German (de)
English (en)
Inventor
Seiichiro Iguchi
Rika Hamamoto
Minoru Yamato
Hiroaki Yamamoto
Yuzo Kimura
Shinsuke Nakagawa
Keigo Yamada
Toshio Nakamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Otsuka Pharmaceutical Factory Inc
Original Assignee
Otsuka Pharmaceutical Co Ltd
Otsuka Pharmaceutical Factory Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd, Otsuka Pharmaceutical Factory Inc filed Critical Otsuka Pharmaceutical Co Ltd
Publication of EP0794778A1 publication Critical patent/EP0794778A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Definitions

  • the present invention relates to a resin particle containing cilostazol as an active ingredient, a medical material and a pharmaceutical preparation containing said resin particle, which is particularly used as an oral
  • Cilostazol exhibits a high thrombocyto-aggregation inhibiting action as well as a phosphodiesterase inhibiting action, anti-ulcerative action, depression action and
  • cilostazol is widely used as an anti-thrombotic agent, cerebrovascular agent, anti-inflammatory agent, anti-hypertensive agent, anti-asthma agent and phosphodiesterase inhibitor.
  • Cilostazol is typically admixed with an excipient and other ingredients and compressed into a tablet form for oral administration.
  • the tablet rapidly disintegrates upon being administered orally, an undesirably large amount of cilostazol is released in a body in a short time, thereby causing side effects such as headache, heavy head feeling and pain.
  • the present inventors have been studied the incorporation of cilostazol in a polymer material to solve the aforesaid problem, and found that a resin particle prepared by incorporating 5 to 90% by weight of cilostazol into an
  • ethylene vinyl alcohol copolymer and granulating the resulting resin into a particle size of not greater than 2,000 ⁇ m can release cilostazol into a body at a controlled rate, thereby ensuring the continuous release of cilostazol into the body over an extended period of time.
  • the inventors have achieved the present invention.
  • a resin particle comprising an ethylene vinyl alcohol copolymer and a cilostazol incorporated therein, the
  • cilostazol being contained in an amount of 5 to 90% by weight for the total amount of the ethylene vinyl alcohol copolymer and the cilostazol, the resin particle having particle size of not greater than 2,000 ⁇ m.
  • the ethylene vinyl alcohol copolymer is highly stable and biologically safe, and is used in various medical materials. Cilostazol is highly dispersible in the ethylene vinyl alcohol copolymer. Therefore, cilostazol is
  • resulting resin is cooled into a solid state.
  • cilostazol and the ethylene vinyl alcohol copolymer are dissolved in a solvent, and then the solvent is removed from the resulting solution to obtain a solid resin.
  • the medical material of the present invention comprises an ethylene vinyl alcohol copolymer and 60 to 85% by weight of cilostazol incorporated therein.
  • the resin particle of the present invention is used singly or in combination with a pharmaceutically available carrier as a pharmaceutical preparation.
  • the ethylene content in the ethylene vinyl alcohol copolymer is appropriately determined depending on the
  • processing method of the resin particle may be generally 27 to 70 mol.%, preferably 38 to 47 mol.%, most preferably 44 to 47 mol.%.
  • An ethylene content of less than 27 mol.% will result in a poor processibility of the ethylene vinyl alcohol copolymer by a melting method which will be described later.
  • an ethylene content of greater than 70 mol.% will result in a poor miscibility of cilostazol with the ethylene vinyl alcohol copolymer.
  • the ethylene vinyl alcohol copolymer has a number-average degree of polymerization of 5,000 to 100,000
  • any of various biologically safe plasticizers, stabilizers, secondary plasticizers, lubricants and like additives may be added to the ethylene vinyl alcohol
  • the ethylene vinyl alcohol copolymer generally has a melting point of 120 to 200°C, preferably 140 to 191°C, most preferably 160 to 175°C. A melting point of lower than 120°C will result in a poor solubility and dispersibility of
  • a melting point of higher than 200°C will cause the decomposition of cilostazol, resulting in a poor processibility of the ethylene vinyl alcohol copolymer and the coloration of the ethylene vinyl alcohol copolymer during the melting process.
  • the content of cilostazol is generally about 5 to 90% by weight, preferably 20 to 85% by weight, more preferably 30 to 85% by weight, where 40 to 85% by weight is preferred and 60 to 85% by weight is most preferred. If the content of cilostazol is less than 5% by weight, desired absorption of cilostazol through oral administration cannot be expected because of excessive release of cilostazol. If the content of cilostazol is greater than 90% by weight, the sustained-release effect is not recognized so that suppression of side effects such as headache cannot be expected.
  • the particle size of the resin particle containing cilostazol is not greater than 2,000 ⁇ m, preferably not greater than 1,000 ⁇ m, most preferably not greater than 600 ⁇ m. More specifically, the particle size is in a range of 75 to 250 ⁇ m, wherein 75 to 150 ⁇ m is preferred and 75 to 105 ⁇ m is most preferred. A particle size of greater than 2,000 ⁇ m is inappropriate, because the release of cilostazol from the inside of particles is excessively suppressed, failing to obtain a desired absorption of cilostazol through oral administration.
  • the melting method is preferably employed in which cilostazol is admixed with the ethylene vinyl alcohol
  • Cilostazol should be homogeneously dispersed in the ethylene vinyl alcohol copolymer without being decomposed during the melting process. For this, the ethylene vinyl alcohol copolymer is melted at a temperature lower than the decomposition point of cilostazol (about
  • the melting and forming processes are performed in an oxygen-free atmosphere to prevent the cilostazol and the copolymer from being oxidized.
  • Moisture contained in the ethylene vinyl alcohol copolymer is preferably removed as much as possible to ensure the stability of the cilostazol and the copolymer and the integrity of the formed resin particle.
  • Any of various melt forming methods can be employed. For example, the melt is formed into a bar shape, drop shape or sheet form by extrusion. Injection molding may otherwise be employed.
  • the resin particle is ground by a grinder and, as required, the resulting particles are sieved to obtain a predetermined particle size.
  • the grinder and grinding conditions to be employed may be appropriately determined depending on a desired particle size and the like.
  • the release of cilostazol from the resin particle formed through the melt forming process can be controlled by appropriately adjusting the content of cilostazol in the resin particle, and the saponification value of and the ethylene content in the ethylene vinyl alcohol copolymer.
  • the release of cilostazol can otherwise be controlled by adding, as required, a plasticizer, stabilizer, secondary plasticizer, lubricant and a like additive to the ethylene vinyl alcohol copolymer.
  • a solution method may be employed.
  • the ethylene vinyl alcohol copolymer and cilostazol are homogeneously dissolved in a solvent, and then the solvent is removed from the solution.
  • the resulting resin is ground in the same manner as described above to obtain the resin particle of the present invention.
  • solvent examples include dimethylformamide, dimethylacetamide, dimethyl sulfoxide, cyclohexanone,
  • aforesaid solvents are used either alone or in combination.
  • 1,1,1,3,3,3-hexafluoro-2-propanol and dimethyl sulfoxide are particularly preferable because the ethylene vinyl alcohol copolymer is highly soluble therein and these solvents can be easily removed by evaporation.
  • Contaminants in the ethylene vinyl alcohol copolymer to be used are preferably preliminarily removed therefrom through sufficient cleaning by means of Soxhlet's extractor. Further, moisture in the copolymer is preferably perfectly removed therefrom by sufficient drying.
  • the solution containing the aforesaid ingredients dissolved therein is spread onto a glass plate or extruded in a bar form, and then the solvent is removed from the solution.
  • the resin particle can be obtained in a film form or bar form.
  • the removal of the solvent is achieved by, for example, air drying, heat drying under a reduced pressure, or phase separation by adding a solidifying agent to the solution.
  • the solidifying agent examples include poor solvents for the ethylene vinyl alcohol copolymer, for example, water, alcohols such as methanol, ethanol, propanol and butanol, and ketones such as acetone. In this case, the diffusion of cilostazol into the solidifying agent during the solidification process should be prevented as much as
  • the release of cilostazol from the resin particle formed by the solution method can be controlled by
  • the release rate of cilostazol can otherwise be controlled by adding, as required, a plasticizer, stabilizer, secondary plasticizer, lubricant and a like additive to the ethylene vinyl alcohol copolymer.
  • the resin particle containing cilostazol can be orally administered to animals or human beings directly or in any of various formulations such as capsule, tablet, granules and suspension which are obtained by mixing the resin particle with a pharmaceutically available carrier.
  • the resin particle may otherwise be administered in a suppository formulation.
  • Formulations such as tablet and capsule for oral administration are prepared in a conventional manner. More specifically, the resin particle of the present invention is mixed with an excipient such as gelatin, starch, lactose, magnesium stearate, talc or gum arabic, and the resulting mixture is compressed into a tablet form. Alternatively, the resin particle is mixed with an inert filler, diluent or the like, and the resulting mixture is filled in a hard gelatin capsule or soft capsule.
  • an excipient such as gelatin, starch, lactose, magnesium stearate, talc or gum arabic
  • the amount of the resin particle to be administered is not particularly limited, but may be appropriately selected from a wide range.
  • the dose of cilostazol is preferably 0.06 to 10mg/lkg-weight per day.
  • the formulation preferably contains 1 to 500mg of the resin particle and may be administered once a day.
  • the medical material of the present invention is suitable for use as, for example, materials for pharmaceutical preparation or medical device which are capable of
  • the medical material can also be provided in medical devices (e.g., platelet bags, extracorporeal
  • the resin particle of the present invention comprises particles of an ethylene vinyl alcohol copolymer and cilostazol incorporated therein in a predetermined proportion, and has a predetermined particle size.
  • EVAL ES-G 110A available from Kuraray Co., Ltd., ethylene content: 47 mol.% in a ground form (sieved with a 28-mesh) was melted and extruded at an extruding temperature of 165 °C by means of a mixing
  • extruder (CS-194A available from Custom Scientific Instruments Inc.).
  • the extruded resin particle was ground by means of a small-scale grinder (SM-1 available from Iuchiseieido).
  • SM-1 available from Iuchiseieido
  • the particles (containing 50% by weight of cilostazol) obtained in EXAMPLE 1 were classified into
  • particle size ranges of 355 to 500 ⁇ m, 250 to 355 ⁇ m, 150 to 250 ⁇ m, 105 to 150 ⁇ m, 75 to 105 ⁇ m, less than 75 ⁇ m, and the other by using sieves specified by JIS (Japanese Industrial Standards).
  • Particles containing 40% by weight of cilostazol were obtained in substantially the same manner as in EXAMPLE 1, except that a mixture of 48g of cilostazol and 72g of an ethylene vinyl alcohol copolymer (EVAL ES-G 110A available from Kuraray Co., Ltd., ethylene content: 47 mol.%) in a ground form (sieved with a 28-mesh) was melted and extruded at an extruding temperature of 165°C.
  • EVAL ES-G 110A available from Kuraray Co., Ltd., ethylene content: 47 mol.
  • the particles (containing 40% by weight of cilostazol) obtained in EXAMPLE 3 were classified into
  • particle size ranges of 105 to 150 ⁇ m, 75 to 105 ⁇ m, less than 75 ⁇ m, and the other.
  • Particles containing 30% by weight of cilostazol were obtained in substantially the same manner as in EXAMPLE 1, except that a mixture of 36g of cilostazol and 84g of an ethylene vinyl alcohol copolymer (EVAL ES-G 110A available from Kuraray Co., Ltd., ethylene content: 47 mol.%) in a ground form (sieved with a 28-mesh) was melted and extruded at an extruding temperature of 165°C.
  • EVAL ES-G 110A available from Kuraray Co., Ltd., ethylene content: 47 mol.
  • the particles (containing 30% by weight of cilostazol) obtained in EXAMPLE 5 were classified into
  • particle size ranges of 105 to 150 ⁇ m, 75 to 105 ⁇ m, less than 75 ⁇ m, and the other.
  • Particles containing 20% by weight of cilostazol were obtained in substantially the same manner as in EXAMPLE 1, except that a mixture of 24g of cilostazol and 96g of an ethylene vinyl alcohol copolymer (EVAL ES-G 110A available from Kuraray Co., Ltd., ethylene content: 47 mol.%) in a ground form (sieved with a 28-mesh) was melted and extruded at an extruding temperature of 165 °C.
  • EVAL ES-G 110A available from Kuraray Co., Ltd., ethylene content: 47 mol.
  • Particles containing 10% by weight of cilostazol were obtained in substantially the same manner as in EXAMPLE 1, except that a mixture of 12g of cilostazol and 108g of an ethylene vinyl alcohol copolymer (EVAL ES-G 110A available from Kuraray Co., Ltd., ethylene content: 47 mol.%) in a ground form (sieved with a 28-mesh) was melted and extruded at an extruding temperature of 165 °C.
  • EVAL ES-G 110A available from Kuraray Co., Ltd., ethylene content: 47 mol.
  • Particles containing 5% by weight of cilostazol were obtained in substantially the same manner as in EXAMPLE 1, except that a mixture of 6g of cilostazol and 114g of an ethylene vinyl alcohol copolymer (EVAL ES-G 110A available from Kuraray Co., Ltd., ethylene content: 47 mol.%) in a ground form (sieved with a 28-mesh) was melted and extruded at an extruding temperature of 165 oC.
  • EVAL ES-G 110A available from Kuraray Co., Ltd., ethylene content: 47 mol.
  • Particles containing 60% by weight of cilostazol were obtained in substantially the same manner as in EXAMPLE 1, except that a mixture of 72g of cilostazol and 48g of an ethylene vinyl alcohol copolymer (EVAL ES-G 110A available from Kuraray Co., Ltd., ethylene content: 47 mol.%) in a ground form (sieved with a 28-mesh) was melted and extruded at an extruding temperature of 165 oC.
  • EVAL ES-G 110A available from Kuraray Co., Ltd., ethylene content: 47 mol.
  • the particles (containing 60% by weight of cilostazol) obtained in EXAMPLE 10 were classified into particle size ranges of 75 to 105 ⁇ m, less than 75 ⁇ m, and the other.
  • Particles containing 70% by weight of cilostazol were obtained in substantially the same manner as in EXAMPLE 1, except that a mixture of 84g of cilostazol and 36g of an ethylene vinyl alcohol copolymer (EVAL ES-G 110A available from Kuraray Co., Ltd., ethylene content: 47 mol.%) in a ground form (sieved with a 28-mesh) was melted and extruded at an extruding temperature of 170 °C.
  • EVAL ES-G 110A available from Kuraray Co., Ltd., ethylene content: 47 mol.
  • the particles (containing 70% by weight of cilostazol) obtained in EXAMPLE 12 were classified into particle size ranges of 75 to 105 ⁇ m, less than 75 ⁇ m, and the other.
  • Particles containing 80% by weight of cilostazol were obtained in substantially the same manner as in EXAMPLE 1, except that a mixture of 96g of cilostazol and 24g of an ethylene vinyl alcohol copolymer (EVAL ES-G 110A available from Kuraray Co., Ltd., ethylene content: 47 mol.%) in a ground form (sieved with a 28-mesh) was melted and extruded at an extruding temperature of 170oC.
  • EVAL ES-G 110A available from Kuraray Co., Ltd., ethylene content: 47 mol.
  • the particles (containing 80% by weight of cilostazol) obtained in EXAMPLE 14 were classified into particle size ranges of 75 to 105 ⁇ m, less than 75 ⁇ m, and the other.
  • Particles containing 90% by weight of cilostazol were obtained in substantially the same manner as in EXAMPLE 1, except that a mixture of 108g of cilostazol and 12g of an ethylene vinyl alcohol copolymer (EVAL ES-G 110A available from Kuraray Co., Ltd., ethylene content: 47 mol.%) in a ground form (sieved with a 28-mesh) was melted and extruded at an extruding temperature of 170°C.
  • EVAL ES-G 110A available from Kuraray Co., Ltd., ethylene content: 47 mol.
  • cilostazol obtained in EXAMPLE 16 were classified into particle size ranges of less than 75 ⁇ m and the other.
  • Particles containing 40% by weight of cilostazol were obtained in substantially the same manner as in EXAMPLE 1, except that a mixture of 48g of cilostazol and 72g of an ethylene vinyl alcohol copolymer (EVAL EP-E 105A available from Kuraray Co., Ltd., ethylene content: 44 mol .% ) in a ground form (sieved with a 28-mesh) was melted and extruded at an extruding temperature of 170oC.
  • EVAL EP-E 105A available from Kuraray Co., Ltd., ethylene content: 44 mol .%
  • the particles (containing 40% by weight of cilostazol) obtained in EXAMPLE 18 were classified into particle size ranges of 75 to 105um and the other.
  • Particles containing 50% by weight of cilostazol were obtained in substantially the same manner as in EXAMPLE 1, except that a mixture of 60g of cilostazol and 60g of an ethylene vinyl alcohol copolymer (EVAL EP-E 105A available from Kuraray Co., Ltd., ethylene content: 44 mol.%) in a ground form (sieved with a 28-mesh) was melted and extruded at an extruding temperature of 170°C.
  • EVAL EP-E 105A available from Kuraray Co., Ltd., ethylene content: 44 mol.
  • the particles (containing 50% by weight of cilostazol) obtained in EXAMPLE 20 were classified into particle size ranges of 75 to 105 ⁇ m and the other.
  • Particles containing 60% by weight of cilostazol were obtained in substantially the same manner as in EXAMPLE 1, except that a mixture of 72g of cilostazol and 48g of an ethylene vinyl alcohol copolymer (EVAL EP-E 105A available from Kuraray Co., Ltd., ethylene content: 44 mol.%) in a ground form (sieved with a 28-mesh) was melted and extruded at an extruding temperature of 170oC.
  • EVAL EP-E 105A available from Kuraray Co., Ltd., ethylene content: 44 mol.
  • the particles (containing 60% by weight of cilostazol) obtained in EXAMPLE 22 were classified into particle size ranges of 75 to 105 ⁇ m and the other.
  • Particles containing 70% by weight of cilostazol were obtained in substantially the same manner as in EXAMPLE 1, except that a mixture of 84g of cilostazol and 36g of an ethylene vinyl alcohol copolymer (EVAL EP-E 105A available from Kuraray Co., Ltd., ethylene content: 44 mol.%) in a ground form (sieved with a 28-mesh) was melted and extruded at an extruding temperature of 175°C.
  • EVAL EP-E 105A available from Kuraray Co., Ltd., ethylene content: 44 mol.
  • the particles (containing 70% by weight of cilostazol) obtained in EXAMPLE 24 were classified into particle size ranges of 75 to 105 ⁇ m and the other.
  • Particles containing 80% by weight of cilostazol were obtained in substantially the same manner as in EXAMPLE 1, except that a mixture of 96g of cilostazol and 24g of an ethylene vinyl alcohol copolymer (EVAL EP-E 105A available from Kuraray Co., Ltd., ethylene content: 44 mol.%) in a ground form (sieved with a 28-mesh) was melted and extruded at an extruding temperature of 175oC.
  • EVAL EP-E 105A available from Kuraray Co., Ltd., ethylene content: 44 mol.
  • the particles (containing 80% by weight of cilostazol) obtained in EXAMPLE 26 were classified into particle size ranges of 75 to 105 ⁇ m and the other.
  • Particles containing 90% by weight of cilostazol were obtained in substantially the same manner as in EXAMPLE 1, except that a mixture of 108g of cilostazol and 12g of an ethylene vinyl alcohol copolymer ( EVAL EP-E 105A available from Kuraray Co., Ltd., ethylene content: 44 mol. % ) in a ground form (sieved with a 28-mesh) was melted and extruded at an extruding temperature of 175oC.
  • EVAL EP-E 105A available from Kuraray Co., Ltd., ethylene content: 44 mol. %
  • the particles (containing 90% by weight of cilostazol) obtained in EXAMPLE 28 were classified into particle size ranges of 75 to 105 ⁇ m and the other.
  • cilostazol can be controlled as desired by appropriately selecting the cilostazol content and particle size.
  • Test preparation 1 Particles having a particle size
  • Test preparation 2 Particles having a particle size range of
  • Test preparation 3 Particles having a particle size range of
  • Test preparation 4 Particles having a particle size range of
  • Control preparation Hydroxypropyl methyl cellulose (HPMC) suspension containing 10mg of cilostazol
  • test preparations and the control preparation each containing 10mg of cilostazol were respectively filled in minicapsules for rats to be used in the absorption test.
  • Cmax maximum cilostazol concentration in blood serum
  • a 200mg of the particles obtained in EXAMPLE 2 (which contains 50% by weight of cilostazol and has a particle size of 75 to 105 ⁇ m) were filled in a capsule to give a capsule containing 100mg of cilostazol.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Cette invention se rapporte à une particule de résine, qui comprend un copolymère éthylène/alcohol de vinyle, et 5 à 90 % en poids de cilostazol incorporé dans ce polymère, et qui possède une grosseur des particules qui n'est pas supérieure à 2000 νm. Lorsqu'elle est administrée par voie orale, cette particule de résine permet de maintenir constante la concentration de cilostazol dans le sang pendant une période prolongée et, par conséquent, elle atténue notablement les effets secondaires, tels que douleurs et maux de tête, qui autrement risquent d'être provoqués par une libération rapide du cilostazol dans le corps.
EP96900177A 1995-01-10 1996-01-04 Particule de resine, substance medicale et preparation pharmaceutique contenant cette particule de resine Withdrawn EP0794778A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP228795 1995-01-10
JP2287/95 1995-01-10
PCT/JP1996/000004 WO1996021448A1 (fr) 1995-01-10 1996-01-04 Particule de resine, substance medicale et preparation pharmaceutique contenant cette particule de resine

Publications (1)

Publication Number Publication Date
EP0794778A1 true EP0794778A1 (fr) 1997-09-17

Family

ID=11525167

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96900177A Withdrawn EP0794778A1 (fr) 1995-01-10 1996-01-04 Particule de resine, substance medicale et preparation pharmaceutique contenant cette particule de resine

Country Status (6)

Country Link
EP (1) EP0794778A1 (fr)
KR (1) KR19980701292A (fr)
CN (1) CN1168102A (fr)
AU (1) AU4357096A (fr)
CA (1) CA2208571A1 (fr)
WO (1) WO1996021448A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006343445B8 (en) * 1998-11-02 2011-06-16 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor
EG23951A (en) * 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
EP1407785A4 (fr) * 2001-06-14 2009-12-02 Otsuka Pharma Co Ltd Compositions medicinales
TWI338583B (en) 2004-05-20 2011-03-11 Otsuka Pharma Co Ltd Solid pharmaceutical formulation
WO2006030301A1 (fr) * 2004-09-17 2006-03-23 Ranbaxy Laboratories Limited Composition pharmaceutique contenant du cilostazol, a base de particules d'une taille inferieure a 50 micrometres
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
KR20080076440A (ko) * 2007-02-16 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
TWI615157B (zh) * 2013-02-06 2018-02-21 大塚製藥股份有限公司 包括不定形西洛他唑的固體分散劑

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH683673A5 (de) * 1991-10-01 1994-04-29 Otsuka Pharma Co Ltd Antithromboseharz, Antithromboseröhrchen, Antithrombosefilm und Antithromboseüberzug.
WO1994014444A1 (fr) * 1992-12-24 1994-07-07 Otsuka Pharmaceutical Co., Ltd. Remede contre le psoriasis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9621448A1 *

Also Published As

Publication number Publication date
CN1168102A (zh) 1997-12-17
MX9705185A (es) 1997-10-31
CA2208571A1 (fr) 1996-07-18
KR19980701292A (ko) 1998-05-15
WO1996021448A1 (fr) 1996-07-18
AU4357096A (en) 1996-07-31

Similar Documents

Publication Publication Date Title
CA2124821C (fr) Dispersions pharmaceutiques solides ameliorees
EP0988863B1 (fr) Complexes stables de composés peu solubles
US4404183A (en) Sustained release pharmaceutical composition of solid medical material
US3773920A (en) Sustained release medicinal composition
EP0381219B1 (fr) Composition à base de gemfibrozil à libération modifiée
JPH0122245B2 (fr)
DE69935609T2 (de) Formulierungen enthaltend cefuroxim-axetil
AU659114B2 (en) Method for the manufacture of a controlled release solid unit dosage form
KR920006908B1 (ko) 디히드로피리딘을 함유하는 고상 약제의 제조 방법
EP0794778A1 (fr) Particule de resine, substance medicale et preparation pharmaceutique contenant cette particule de resine
JP2004131393A (ja) 易溶出性製剤
JPH0813736B2 (ja) 単斜結晶構造を有する熱―、光―、及び湿気―感受性活性成分を含む錠剤又は糖剤組成物の調製方法
DE69910188T2 (de) Arzneiformen enthaltend carvedilol
JPH04230209A (ja) 徐放性医薬製剤およびそれの調製方法
CA2878689A1 (fr) Formes cristallines d'un inhibiteur du vhc
JPH08245389A (ja) 樹脂粒状物、医療用材料および前記樹脂粒状物を含有する医薬製剤
JPH029007B2 (fr)
JPH031288B2 (fr)
JPS62228017A (ja) ジヒドロピリジンを含有する固体の迅速放出性薬剤調製物の製造方法
CA2280925A1 (fr) Cefuroxime axetil stabilise
MXPA97005185A (en) Particle of resin, medical material and pharmaceutical preparation containing such particle of res
EP0209121A2 (fr) Composition pharmaceutique à libération contrôlée et retardée ainsi qu'un procédé pour sa préparation
CH670201A5 (en) Solid dispersions of water-insol. drugs - comprising coherent crystals of drug in water-soluble matrix
JPH08175997A (ja) マレイン酸イルソグラジン経口投与用製剤およびその製造法
WO2002083101A1 (fr) Comprimes de nimodipine a liberation controlee et leur procede de fabrication

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970703

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: NAKAMURA, TOSHIO

Inventor name: YAMADA, KEIGO

Inventor name: NAKAGAWA, SHINSUKE

Inventor name: KIMURA, YUZO

Inventor name: YAMAMOTO, HIROAKI

Inventor name: YAMATO, MINORU

Inventor name: HAMAMOTO, RIKA

Inventor name: IGUCHI, SEIICHIRO

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19980401